Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) and Merck KGaA (OTCMKTS:MKKGY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
Profitability
This table compares Ensysce Biosciences and Merck KGaA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ensysce Biosciences | -280.53% | -2,550.30% | -320.49% |
| Merck KGaA | 11.20% | 8.10% | 4.58% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Ensysce Biosciences and Merck KGaA, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ensysce Biosciences | 1 | 0 | 1 | 0 | 2.00 |
| Merck KGaA | 1 | 5 | 0 | 0 | 1.83 |
Ensysce Biosciences currently has a consensus price target of $2.00, indicating a potential upside of 375.06%. Given Ensysce Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Ensysce Biosciences is more favorable than Merck KGaA.
Volatility and Risk
Ensysce Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
Valuation and Earnings
This table compares Ensysce Biosciences and Merck KGaA”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ensysce Biosciences | $5.07 million | 1.62 | -$10.18 million | ($2.76) | -0.15 |
| Merck KGaA | $23.87 billion | 0.91 | $2.95 billion | $1.94 | 17.36 |
Merck KGaA has higher revenue and earnings than Ensysce Biosciences. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Merck KGaA, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 0.1% of Merck KGaA shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
About Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
